Literature DB >> 3780828

Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.

J N Colin, R Farinotti, G Fredj, M Tod, J P Clavel, E Vignon, F Dietlin.   

Abstract

Previous studies have described a pharmacokinetic interaction between probenecid, a uricosuric drug, and oxipurinol, the major metabolite of allopurinol. In single dose studies, no interaction was found to occur between benzbromarone, another uricosuric agent, and oxipurinol. A cross over study was conducted in 12 volunteers to compare the kinetics of allopurinol and oxipurinol following treatment for 7 days with allopurinol alone or combined with benzbromarone 20 or 100 mg. The pharmacokinetic parameters of allopurinol were not modified by the uricosuric therapy, but those of oxipurinol were markedly altered by concurrent administration even of the lower dose of benzbromarone; the average plasma level fell by 30% and the renal elimination rate was increased by 50%. A parallel increase in the renal elimination rate of uric acid was observed (significant only with the higher dose of benzbromarone) and a positive linear correlation between the fractional excretion of uric acid and that of oxipurinol was established.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3780828     DOI: 10.1007/bf00870986

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Effect of single oral doses of benzbromarone on serum and urinary uric acid.

Authors:  A K Jain; J R Ryan; F G McMahon; R J Noveck
Journal:  Arthritis Rheum       Date:  1974 Mar-Apr

2.  Renal clearance of oxipurinol, the chief metabolite of allopurinol.

Authors:  G B Elion; T F Yü; A B Gutman; G H Hitchings
Journal:  Am J Med       Date:  1968-07       Impact factor: 4.965

3.  [Excretion and serum concentrations of allopurinol, oxipurinol and oxipurines in combined treatment with allopurinol and benzbromarone in increasing doses].

Authors:  D P Mertz; K Borner
Journal:  Med Welt       Date:  1983-09-09

4.  [Influence of benzbromarone on the pharmacokinetics and pharmacodynamics of oxipurinol].

Authors:  C Rüffer; G Zorn; E Henkel; H J Mitzkat
Journal:  Arzneimittelforschung       Date:  1982

5.  Statistical moments in pharmacokinetics.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

6.  Quantitative liquid chromatography of allopurinol and oxypurinol in human plasma and urine.

Authors:  J M Failler; R Farinotti; A Dauphin
Journal:  Ther Drug Monit       Date:  1985       Impact factor: 3.681

7.  [Effect of uric acid lowering drugs in low dosage in patients with hyperuricemia and hypertriglyceridemia in a randomized group study].

Authors:  H R Arntz; H R Dreykluft; H Leonhardt
Journal:  Fortschr Med       Date:  1979-07-19

8.  Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.

Authors:  B Breithaupt; M Tittel
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  [Uric acid-lowering effect of a combination of benzbromarone and allopurinol--studies under standardized dietary conditions].

Authors:  W Löffler; W Gröbner; N Zöllner
Journal:  Arzneimittelforschung       Date:  1983
  9 in total
  7 in total

1.  [Differential indications for uricosuric drugs and allopurinol].

Authors:  W Gröbner; N Zöllner
Journal:  Klin Wochenschr       Date:  1989-03-01

2.  Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.

Authors:  K Turnheim; P Krivanek; R Oberbauer
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

3.  Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol.

Authors:  T Yamamoto; Y Moriwaki; S Takahashi; M Suda; K Higashino
Journal:  Ann Rheum Dis       Date:  1991-09       Impact factor: 19.103

Review 4.  Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Authors:  Richard O Day; Garry G Graham; Mark Hicks; Andrew J McLachlan; Sophie L Stocker; Kenneth M Williams
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

5.  Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.

Authors:  Sophie L Stocker; Kenneth M Williams; Andrew J McLachlan; Garry G Graham; Richard O Day
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

6.  Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout.

Authors:  Martin Kankam; Jesse Hall; Michael Gillen; Xiaojuan Yang; Zancong Shen; Caroline Lee; Sha Liu; Jeffrey N Miner; Susan Walker; Vicki Clauson; David Wilson; Mai Nguyen
Journal:  J Clin Pharmacol       Date:  2018-05-07       Impact factor: 3.126

7.  Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol.

Authors:  Fernando Perez-Ruiz; John S Sundy; Jeffrey N Miner; Matthew Cravets; Chris Storgard
Journal:  Ann Rheum Dis       Date:  2016-01-07       Impact factor: 19.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.